Results 151 to 160 of about 11,301 (165)
Some of the next articles are maybe not open access.
PCSK9 inhibitors for treating hypercholesterolemia
Expert Opinion on Pharmacotherapy, 2020Introduction: Scientific evidence on subjects treated with statin or other lipid-lowering treatments has established that treatments aiming to lower low-density lipoprotein cholesterol (LDL-C) can reduce atherosclerosis. PCSK9 inhibitors (PCSK9-i), thanks to their efficacy in reducing LDL-C constitute a further step in the treatment of dyslipidemia and
Pasta A. +8 more
openaire +2 more sources
Current Opinion in Lipidology, 2013
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire +2 more sources
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire +2 more sources
Lipid lowering with PCSK9 inhibitors
Nature Reviews Cardiology, 2014Statins are the most-effective therapy currently available for lowering the LDL-cholesterol (LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for patients who cannot reach the target LDL-C level when taking the maximum-tolerated dose of a statin.
Razvan T, Dadu, Christie M, Ballantyne
openaire +2 more sources
PCSK9 inhibitors and cardiovascular outcomes
Expert Opinion on Biological Therapy, 2019Introduction: Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering drugs are beneficial for the primary and secondary prevention of cardiovascular (CV) disease.
Daniel, Steffens +6 more
openaire +2 more sources
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Current Cardiology Reports, 2013Despite the efficacy of statin therapy, patients treated with these agents face substantial residual risk that is associated with achieved levels of LDL cholesterol (LDL-C). These observations suggest a potential benefit of additional strategies to promote further LDL-C reduction.
Rose Q, Do +2 more
openaire +2 more sources
Third generation PCSK9-inhibitors
European Heart Journal, 2023Ulrich Laufs +2 more
openaire +3 more sources
PCSK9 inhibitors: clinical evidence and implementation
Nature Reviews Cardiology, 2018The gene encoding PCSK9 was first identified and linked to the phenotype of familial hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role of PCSK9 in the regulation of LDL-receptor recycling and identified loss-of-function variants of PCSK9 that were associated with low circulating levels of LDL cholesterol (LDL-C ...
openaire +2 more sources
New Oral PCSK9 Inhibitor: “MK-0616”
Cardiology in ReviewMK-0616, a novel oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), represents a significant advancement in the treatment of hypercholesterolemia. Unlike current PCSK9 inhibitors, which are injectable monoclonal antibodies and siRNA molecules, MK-0616 offers a patient-friendly alternative. The development of MK-
Zoya, Siddiqui, William, Frishman
openaire +2 more sources
PCSK9 Inhibitors and Cardiovascular Events
New England Journal of Medicine, 2015Marc S, Sabatine +2 more
openaire +5 more sources
Familial hypercholesterolaemia: PCSK9 inhibitors are coming
The Lancet, 2015Raul D, Santos, Gerald F, Watts
openaire +2 more sources